New Report Says Nano-Enabled Drug Discovery Market to Reach $1.3 Billion by 2009

Mar 08, 2005, 00:00 ET from NanoMarkets

    STERLING, Va., March 8 /PRNewswire/ -- According to a new report by
 NanoMarkets, an industry consultancy based here, nano-enabled drug discovery
 solutions will generate revenues of $1.3 billion in 2009 and grow to $2.5
 billion in 2012.  The firm projects that labs-on-a-chip and arrays will offer
 the largest opportunities with nanoparticulate-based solutions also showing
 significant growth.  The report titled, "The Impact of Nanotechnology in Drug
 Discovery: Global Developments, Market Analysis and Future Prospects" is now
 shipping to clients.  Additional details can be found at the firm's website,
     NanoMarkets' new 218-page report provides an in-depth analysis of all the
 drivers, restraints, challenges, regulatory issues and government funding
 policies that impact nano-enabled drug discovery, along with profiles of the
 regulatory and funding environments for this kind of technology in 20 major
 countries.  This report also provides eight-year forecasts that break out the
 market by key applications segments and product types and it offers profiles
 of 30 firms already active in this space.
     Key Insights:
     NanoMarkets' research indicates that nanotechnology will provide tangible
 benefits to the drug discovery process through:
     *  Improved understanding of chemicals at the cellular/molecular level
     *  Improved identification and validation of target proteins and drugs
     *  Increased throughput
     *  Reduced time for the identification of new drugs
     *  Reduced amount of precious reagents required to carry out screening of
        potential drugs
     *  Improved visualization of drug interactions
     NanoMarkets says that the impact of nano-enabled drug discovery is
 expected to be both broad and deep, affecting numerous areas of the drug
 discovery process.  The new report predicts that by 2009 19 percent of nano-
 enabled drug discovery revenues will come from the control and analysis of
 cells, while another 13 percent will come from DNA/RNA sizing,
 electropheroresis and quantitation.  Genotyping will account for another 11
 percent of revenues and high-throughput screening will take another 10 percent.
     Nanotechnology has already enabled new formulations for drugs -- for
 example, the FDA-approved Abraxane from American Pharmaceuticals, which has
 indications for the treatment of metastable breast cancers. Other drugs that
 are in R&D pipeline or in regulatory approval stage are those developed by
 NanoHorizons for the treatment of skin disorders and infections.
     The new NanoMarkets' report goes on to claim that the companies that are
 in the best position to benefit from the move towards nano-enabled solutions
 in drug discovery are the major microfluidics and lab-on-chip companies.
 Such companies include Aclara, Agilent, Caliper, Cepheid, CombiMatrix,
 Eksigent, Gyros, Nanogen and Nanostream.  NanoMarkets also says that Quantum
 Dot Corp. is likely to fare well as it holds several key international patents
 on semiconducting nanocrystal technology, as well as having established
 relationships with GlaxoSmithKline, Pfizer and Genentech, where Qdots are
 being used for high-throughput screening.  NanoMarkets sees opportunities for
 self-assembly firms such as 3DM and C Sixty in the future because they are
 offering new solutions, not just for drug discovery, but also for drug
 delivery and diseases prevention.
     About NanoMarkets:
     NanoMarkets analyzes the impact of nanotechnology on both established and
 emerging markets with a focus on the realms of communications, IT,
 semiconductors, bio-medicine and energy. The firm provides market research
 reports, customized industry analyses and general market commentary for
 companies looking to capitalize on nanotechnology-based opportunities.

SOURCE NanoMarkets